Revista Periodontia MAR 2012.indd - Revista Sobrape

channels counterbalance the impaired endothelium-dependent
vasodilation in stroke-prone spontaneously hypertensive rats. Transl
Res 2009;154(4):183-193.
63- Foudi N, Louedec, Cachina T, Brink C, Norel X. Selective cyclooxygenase-2
inhibition directly increases human vascular reactivity to norepinephrine
during acute inflammation. Cardiovascular Research 2009; 81:269-
277.
64- Bulut D, Liaghat S, Hanefeld C, Koll R, Miebach T, Mugge A.
Selective cyclooxygenase-2 inhibition with parecoxib acutely impairs
endothelium-dependent vasodilatation in patients with essential
hypertension. J Hypertens 2003; 21(9):1663-1667.
65- Nacci C, Tarquinio M, Benedictis LD, Mauro A. Zigrino A, Csrratù MR
et al. Endothelial dysfunction in mice with streptozotocin-induced
type 1 diabetes in opposed by compensatory overexpression of
cyclooxygenase-2 in the vasculature. Endocrinology 2009; 150(2):849-
861.
66- Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et
al. Role of prostacyclin in the cardiovascular response to thromboxane
A2. Science 2002; 296:539–541.
67- Smyth EM, FitzGerald GA. Human prostacyclin receptor. Vitam Horm
2002; 65:149–165.
68- Hinz B, Brune K. Cyclooxygenase-2 – 10 years later. J Pharmacol Exp
Ther 2002; 300(2):367-375.
69- Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other
Lipid Mediat 2002; 68/69:165–175.
70- Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging
out with nuclear receptors. Endocrinology 2002; 143:3207–3210.
71- Bishop-Bailey D, Mitchell JA, Warner TD. COX-2 in cardiovascular
disease. Arterioscler Thromb Vasc Biol 2006; 26:956-958.
72- Kawabe J, Ushikubi F, Hasebe N. Prostacyclin in vascular diseases –
Recent insights and future perspectives. Circ J 2010; 74:836-843.
73- Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular
consequences of COX-2 inhibition: therapeutic challenges and
opportunities. J Clin Invest 2006; 116(1):4-15.
74- Huber MA, Terezhalmy GT. The use of COX-2 inhibitors for acute
dental pain: A second look. J Am Dent Assoc 2006; 137:480-487.
75- Shi S, Klotz U. Clinical use and pharmacological properties of selective
COX-2 inhibitors. Eur J Clin Pharmacol 2008; 64:233-252.
76- Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2
inhibitors raise blood pressure more than nonselective NSAIDs and
placebo? An update meta-analysis. J Hipertens 2009; 27:2332-2341.
77- FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;
351:1709–1711.
78- Zhang F, Engebretson SP, Morton RS, Cavanaugh JR PF, Subbaramaiah
K, Dannenberg AJ. The overexpression of cyclo-oxygenase-2 in chronic
periodontitis. Am Dent Assoc 2003; 134:861-867.
An official publication of the Brazilian Society of Periodontology ISSN-0103-9393
Braz J Periodontol - March 2012 - volume 22 - issue 01 - 22(1):16-25
79- Noguchi K, Ishikawa I. The roles of cyclooxygenase-2 and prostaglandin
E2 in periodontal disease. Periodontol 2000 2007; 43:85-101.
80- Holzhausen M, Spolidorio DM, Muscará MN, Hebling J, Spolidorio
LC. Protective effects of etoricoxib, a selective inhibitor of
cyclooxygenase-2, in experimental periodontitis in rats. J Periodontal
Res 2005; 40(3):208-211.
81- Azoubel MC, Menezes AM, Bezerra D, Oriá RB, Ribeiro RA, Brito
GA. Comparison of etoricoxib and indomethacin for the treatment
of experimental periodontitis in rats. Braz J Med Biol Res 2007;
40(1):117-125.
82- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxemius B, Horgan K
et al. Cardiovascular events associated with rofecoxib in a colorectal
adenoma chemoprevention trial. N Engl J Med 2005; 352(11):1092-
1102.
83- Steffens JP, Santos FA, Sartori R, Pilatti GL. Preemptive dexamethasone
and etoricoxib for pain and discomfort prevention after periodontal
surgery: a double-masked, crossover, controlled clinical trial. J
Periodontol 2010; 81(8):1153-1160.
84- Mercado FB, Marshall RI, Klestov AC, Barttold PM. Relationship
between rheumatoid arthritis and periodontitis. J Periodontol 2001;
72(4):779-787.
85- Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis:
the humoral immune response to oral bacteria provides a stimulus
for the development of rheumatoid arthritis. Inflammation 2004;
28(6):311-308.
86- Pischon N, Pischon T, Kröger J, Gülmez E, Kleber B-M, Bernimoulin
J-P et al. Association among rheumatoid arthritis, oral hygiene, and
periodontitis. J Periodontol 2008; 79:979-986.
87- Georgiou TO, Marshall RI, Bartold PM. Prevalence of systemic diseases
in Brisbane general and periodontal practice patients. Aust Dent J
2004; 49(4):177-184.
88- De Pablo P, Dietrich T, McAlindon TE. Association of periodontal
disease amd tooth loss with rheumatoid arthritis in the US population.
J Rheumatol 2008; 35(1):70-76.
Endereço para correspondência:
Daniel Fernandes
Universidade Estadual de Ponta Grossa
Campus Universitário, Bloco M, sala 13
Av. Carlos Cavalcanti, 4748 - Uvaranas
CEP: 84030-900 - Ponta Grossa – PR
E-mail: dfernandes@uepg.br
25